
Qantas (ASX: QAN) has pulled back sharply in 2026, but the decline is largely driven by cyclical pressures rather than a broken business. The key trigger has been a surge in jet fuel costs, which have more than doubled in recent months.

Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.

This report highlights three high-yield ASX dividend stocks across different industries, offering strong income and upside potential over the next 6–12 months, backed by durable competitive advantages, profitable business models, and valuations that appear attractive relative to their long-term growth prospects.

CSL shares crashed after a US$5 billion impairment warning and weaker guidance shocked investors, sending the stock below A$100. Despite strong long-term fundamentals in plasma therapies, technical indicators remain bearish with heavy selling pressure still dominating the chart.

Fortescue (ASX: FMG) shares have rebounded on stronger iron ore prices, improving Chinese demand and solid shipments. Sentiment is also lifted by dividends and production strength, while its green energy transition and decarbonisation plans support long-term growth above A$20 momentum.

Elders' shares fell over 20% after investors focused on weaker FY26 guidance, rising input and fuel costs, integration risks, despite strong half-year earnings growth driven by better conditions and Delta Agribusiness contributions, highlighting concerns about future margins and outlook uncertainty.
...